Scholars Central

PerspectivePublished 18 May 2021

Short note on cancer immunotherapy

Authors: Christiana Williams

Clinical Investigation

Volume 11 · Issue 5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cancer immunotherapy comprises the use of immunological agents such as cytokines, vaccines, cell treatments, and humoral, transfection agents to manipulate the immune system. The antitumor response of the host must be boosted by increasing the number of effector cells and soluble mediator production, while suppressor mechanisms must be lowered by creating a tumor-killing environment and modulating immunological checkpoints. Immunotherapy appears to work better in more immunogenic tumors. Bladder cancer was the initial indication for immunotherapy in 1970. Immune checkpoint inhibitors are a hot issue in bladder cancer clinical trials. Despite the notion that breast cancer is immunologically silent, several preclinical and clinical studies have shown that immunotherapy can improve breast cancer patients’ clinical outcomes. Cervical cancer, brain cancer, head and neck cancer, colorectal cancer, and esophageal cancer are all getting new immune-based cancer treatments.

Keywords

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Christiana Williams”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels